var data={"title":"Dalteparin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dalteparin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5973?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dalteparin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dalteparin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dalteparin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dalteparin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708690\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Spinal/Epidural hematoma:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWHs) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; or a history of spinal deformity or spinal injury. Optimal timing between the administration of dalteparin and neuraxial procedures is not known.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156480\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fragmin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156481\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fragmin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156518\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Low Molecular Weight Heparin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156483\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Each 2,500 units of anti-Xa activity is equal to dalteparin 16 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anticoagulant for hemodialysis and hemofiltration (off-label use):</b> IV: (Fragmin Canadian product labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic renal failure with no other bleeding risks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis/filtration &le;4 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV bolus: 5,000 units; may adjust dose during subsequent dialysis sessions in increments of 500 to 1,000 anti-Xa units based on the outcome of the previous dialysis session<b>. </b>Alternatively, may administer an IV bolus of 30 to 40 units/kg, followed by an infusion of 10 to 15 units/kg/hour. <b>Note: </b>Both regimens typically produce plasma concentrations of 0.5 to 1 units anti-Xa/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis/filtration &gt;4 hours: IV bolus: 30 to 40 units/kg, followed by an infusion of 10 to 15 units/kg/hour (typically produces plasma concentrations of 0.5 to 1 units anti-Xa/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute renal failure and high bleeding risk: IV bolus: 5 to 10 units/kg, followed by an infusion of 4 to 5 units/kg/hour (typically produces plasma concentrations of 0.2 to 0.4 units anti-Xa/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>DVT (with or without PE; noncancer-related) treatment (off-label use):</b> SubQ: 200 units/kg once daily (AHA [Jaff 2011]; Feissinger 1996; Wells 2005). <b>Note:</b> In patients with VTE and <i>without</i> cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) (Kearon 2012; Kearon 2016). In patients transitioning to warfarin, start warfarin on the first treatment day and continue dalteparin until INR is &ge;2 for at least 24 hours (usually 5 to 7 days) (ACCP [Guyatt 2012]). Duration of therapy is based on the cause of VTE, risk of recurrence, and risk of bleeding. Refer to guidelines for specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations (Fragmin Canadian product labeling):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: 200 units/kg once daily (maximum dose: 18,000 units/day) <b>or</b> alternatively, may adapt dose as follows (SubQ):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">46 to 56 kg: 10,000 units once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">57 to 68 kg: 12,500 units once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">69 to 82 kg: 15,000 units once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;83 kg: 18,000 units once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (patients with increased bleeding risk): 100 units/kg as continuous infusion over 12 hours may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Obesity:</i> Use actual body weight to calculate dose; a fixed upper dose limit is not recommended; however, increased monitoring may be warranted (see Monitoring Parameters) (Nutescu 2009). One study demonstrated similar anti-Xa levels after 3 days of therapy in obese patients (&gt;40% above IBW; range: 82 to 190 kg) compared to those &le;20% above IBW or between 20% to 40% above IBW (Wilson 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pregnant women (off-label use):</i> 200 units/kg/dose once daily or 100 units/kg/dose every 12 hours. Discontinue &ge;24 hours prior to the induction of labor or cesarean section. Dalteparin therapy may be substituted with heparin near term. Continue anticoagulation therapy for &ge;6 weeks postpartum (minimum duration of therapy: 3 months). LMWH or heparin therapy is preferred over warfarin during pregnancy (Bates 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>DVT prophylaxis: Note: </b>In morbidly obese patients (BMI &ge;40 kg/m<sup>2</sup>), increasing the prophylactic dose by 30% may be appropriate (Nutescu 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Abdominal surgery:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low-to-moderate DVT risk:</i> SubQ: 2,500 units 1 to 2 hours prior to surgery, then 2,500 units once daily for 5 to 10 days postoperatively.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>High DVT risk:</i> SubQ: 5,000 units the evening prior to surgery and then 5,000 units once daily for 5 to 10 days postoperatively. Alternatively in patients with malignancy: 2,500 units 1 to 2 hours prior to surgery, 2,500 units 12 hours later, then 5,000 units once daily for 5 to 10 days postoperatively.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Total hip replacement surgery:</b> SubQ:<b> Note:</b> Three treatment options are currently available. Dose is usually given for 5 to 10 days, although up to 14 days of treatment have been tolerated in clinical trials. The American College of Chest Physicians (ACCP) recommends a minimum duration of at least 10 to 14 days; extended duration of up to 35 days is suggested (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Postoperative regimen:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 2,500 units 4 to 8 hours after surgery (or later if hemostasis not achieved). The ACCP recommends initiation &ge;12 hours after surgery if postoperative regimen chosen (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 5,000 units once daily; allow at least 6 hours to elapse after initial postsurgical dose (adjust administration time accordingly).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preoperative regimen (starting day of surgery):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 2,500 units within 2 hours <b>before</b> surgery. The ACCP recommends initiation &ge;12 hours before surgery if preoperative regimen chosen (Guyatt 2012). At 4 to 8 hours <b>after</b> surgery (or later if hemostasis not achieved), administer 2,500 units.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 5,000 units once daily; allow at least 6 hours to elapse after initial postsurgical dose (adjust administration time accordingly).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preoperative regimen (starting evening prior to surgery):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 5,000 units 10 to 14 hours <b>before</b> surgery. The ACCP recommends initiation &ge;12 hours before surgery if preoperative regimen chosen (Guyatt 2012). At 4 to 8 hours <b>after</b> surgery (or later if hemostasis not achieved), administer 5,000 units.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 5,000 units once daily, allowing 24 hours between doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immobility during acute illness:</b> SubQ: 5,000 units once daily; in clinical trials, the usual duration of therapy was 12 to 14 days. In hospitalized cancer patients, the recommended duration of therapy is length of hospital stay or until fully ambulatory (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Major surgery in cancer patients (off-label): </b>SubQ: 2,500 units 2 to 4 hours prior to surgery, then 5,000 units once daily thereafter <b>or </b>5,000 units 10 to 12 hours prior to surgery, then 5,000 units once daily thereafter; treatment duration should be at least 7 to 10 days. Prolonged treatment up to 4 weeks should be considered in patients undergoing major abdominal or pelvic surgery for cancer with high-risk features (eg, limited mobility, obesity, VTE history, comorbid conditions) (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General surgery with risk factors for VTE (off-label use):</b> SubQ: 2,500 units 1 to 2 hours preoperatively followed by 2,500 to 5,000 units every morning (may administer 2,500 units no sooner than 4 hours after surgery and 8 hours after previous dose provided hemostasis has been achieved) or if other risk factors are present (eg, malignancy, heart failure), then may administer 5,000 units the evening prior to surgery followed by 5,000 units every evening postoperatively; continue treatment until patient is mobilized (approximately &ge;5 to 7 days) (Fragmin Canadian product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mechanical heart valve (aortic or mitral position) to bridge anticoagulation (off-label use): </b>SubQ: 100 units/kg/dose every 12 hours (ACCP [Douketis 2012]). <b>Note:</b> If used in pregnant patients, target anti-Xa level of 0.8 to 1.2 units/mL, 4 to 6 hours postdose (AHA/ACC [Nishimura 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of recurrent venous thromboembolism in pregnancy (off-label use):</b> SubQ: 5,000 units once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism, acute (treatment) (noncancer-related) (off-label use):</b> SubQ: 200 units/kg once daily (Kovacs 2000). <b>Note:</b> In patients with VTE and <i>without</i> cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) (Kearon 2012; Kearon 2016). In patients transitioning to warfarin, start warfarin on the first treatment day and continue dalteparin until INR is &ge;2 for at least 24 hours (usually 5 to 7 days) (ACCP [Guyatt 2012]). Duration of therapy is based on the cause of VTE, risk of recurrence, and risk of bleeding. Refer to guidelines for specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Unstable angina or non-Q-wave myocardial infarction:</b> SubQ: 120 units/kg (maximum dose: 10,000 units) every 12 hours with concurrent aspirin therapy. Discontinue dalteparin once patient is clinically stable; usual duration of therapy is 5 to 8 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Obesity:</i> Use actual body weight to calculate dose; dose capping at 10,000 units recommended (Nutescu 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous thromboembolism, extended treatment in cancer patients:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial (month 1): 200 units/kg (maximum dose: 18,000 units) once daily for 30 days, followed by maintenance therapy during months 2 to 6</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance (months 2 to 6): 150 units/kg (maximum dose: 18,000 units) once daily. Alternatively, warfarin may be used for maintenance therapy; however, meta-analyses and randomized control trials have validated the superiority of LMWH over warfarin. If warfarin is to be used for maintenance therapy, overlap dalteparin with warfarin for a minimum of 5 to 7 days and continue until INR in therapeutic range for at least 48 hours (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance beyond 6 months (off-label): ACCP and ASCO guidelines for VTE prophylaxis/treatment recommend considering continuing anticoagulation beyond 6 months in selected patients due to the persistent high risk of recurrence in those with active cancer; consider risk vs benefit of bleeding and recurrence (Kearon 2012; Kearon 2016; Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment:</i> If platelet count between 50,000 to 100,000/mm<sup>3</sup>, reduce daily dose by 2,500 units until platelet count recovers to &ge;100,000/mm<sup>3</sup>. If platelet count &lt;50,000/mm<sup>3</sup>, discontinue dalteparin until platelet count recover to &gt;50,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Obesity:</i> Use actual body weight to calculate dose; a fixed upper dose limit is not recommended, however, increased monitoring may be warranted (see monitoring parameters) (Nutescu 2009). However, the manufacturer recommends a maximum dose of 18,000 units per day; ASCO guidelines on VTE prophylaxis/treatment in patients with cancer states the optimal dose in patients &gt;120 kg is unclear (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conversion</b>\n      <b>: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from IV unfractionated heparin (UFH) infusion to SubQ dalteparin (Nutescu 2007)</i>: Calculate specific dose for dalteparin based on indication, discontinue UFH and begin dalteparin within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from SubQ dalteparin (therapeutically dosed) to IV UFH infusion (Nutescu 2007)</i>: <b>Note:</b> The following recommendations are based on use of therapeutic doses of dalteparin (eg, 100 units/kg twice daily). If converting from a prophylactic dalteparin dose (eg, 5,000 units once daily) to a therapeutic IV UFH dose, there should not be any delay in starting the IV UFH infusion and may include an UFH bolus/loading dose, when indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinue dalteparin, calculate specific dose for IV UFH infusion based on indication, omit UFH bolus/loading dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Converting from SubQ dalteparin dosed every 12 hours:</i> Start IV UFH infusion 10 to 11 hours after last dose of dalteparin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Converting from SubQ dalteparin dosed every 24 hours:</i> Start IV UFH infusion 22 to 23 hours after last dose of dalteparin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156484\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804012\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution in severe renal impairment; accumulation may occur with repeated dosing, increasing the risk for bleeding. Accumulation was not observed in critically ill patients with severe renal insufficiency (CrCl &lt;30 mL/minute) receiving prophylactic doses (5,000 units/day) for a median of 7 days (Douketis 2008). In cancer patients, receiving treatment for venous thromboembolism, if CrCl &lt;30 mL/minute, manufacturer recommends monitoring anti-Xa levels to determine appropriate dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7676342\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution in patients with severe hepatic impairment; accumulation may occur with repeated dosing, increasing the risk for bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330557\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156459\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fragmin: 25,000 units/mL (3.8 mL [DSC]); 95,000 units/3.8 mL (3.8 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fragmin: 10,000 units/mL (1 mL); 2500 units/0.2 mL (0.2 mL); 5000 units/0.2 mL (0.2 mL); 7500 units/0.3 mL (0.3 mL); 12,500 units/0.5 mL (0.5 mL); 15,000 units/0.6 mL (0.6 mL); 18,000 units/0.72 mL (0.72 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156445\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156462\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: For deep SubQ injection; do not administer IM. May inject in a U-shape to the area surrounding the navel, the upper outer side of the thigh, or the upper outer quadrangle of the buttock. Use thumb and forefinger to lift up a fold of skin when injecting in the navel area or thigh. Insert entire needle length at a 45- to 90-degree angle. Do not expel air bubble from prefilled syringe prior to injection. Air bubble (and extra solution, if applicable) may be expelled from graduated syringes. In order to minimize bruising, do not rub injection site. Rotate injection sites daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">To convert from IV unfractionated heparin (UFH) infusion to SubQ dalteparin (Nutescu 2007): Calculate specific dose for dalteparin based on indication, discontinue UFH and begin dalteparin within 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">To convert from SubQ dalteparin to IV UFH infusion (Nutescu 2007): Discontinue dalteparin; calculate specific dose for IV UFH infusion based on indication; omit heparin bolus/loading dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Converting from SubQ dalteparin dosed every 12 hours:</i> Start IV UFH infusion 10 to 11 hours after last dose of dalteparin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Converting from SubQ dalteparin dosed every 24 hours:</i> Start IV UFH infusion 22 to 23 hours after last dose of dalteparin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV (off-label route): May administer as a bolus IV injection or as a continuous infusion; recommended concentration for infusion: 20 units/mL (Fragmin Canadian product labeling).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156460\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep vein thrombosis prophylaxis:</b> Prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE), in patients requiring abdominal surgery who are at risk for thromboembolism complications (eg, &gt;40 years, obesity, malignancy, history of DVT or PE, surgical procedures requiring general anesthesia lasting &gt;30 minutes); patients undergoing hip-replacement surgery; or in patients who are at risk for thromboembolism complications due to severe immobility during an acute illness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Unstable angina/non-Q-wave myocardial infarction</b>\n      <b>:</b> Prevention of ischemic complications in patients with unstable angina or non-Q-wave myocardial infarction on concurrent aspirin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous thromboembolism, extended treatment in cancer patients: </b>Extended treatment (6 months) of acute symptomatic venous thromboembolism (DVT and/or PE) to reduce the recurrence of venous thromboembolism in cancer patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> In patients with VTE and cancer, ACCP recommends low molecular weight heparin (LMWH) over oral anticoagulants for initial and long-term treatment (Kearon 2012; Kearon 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25590042\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Deep vein thrombosis (with or without pulmonary embolism; noncancer related) treatment; Mechanical prosthetic valve (bridge); Pulmonary embolism, acute (treatment; noncancer related); Venous thromboembolism (VTE) during pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174521\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">National Patient Safety Goals:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring, and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient's laboratory values will remain within or close to normal values (NPSG.03.05.01).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156452\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> As with all anticoagulants, bleeding is the major adverse effect of dalteparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Hematologic &amp; oncologic: Hemorrhage (3% to 14%), thrombocytopenia (including heparin-induced thrombocytopenia, &lt;1%; cancer clinical trials: ~11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Major hemorrhage (&le;6%), wound hematoma (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&gt;3 x ULN: 4% to 10%), increased serum AST (&gt;3 x ULN: 5% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (&le;12%), hematoma at injection site (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% (Limited to important or life-threatening): Alopecia, anaphylactoid reaction, gastrointestinal hemorrhage, hemoptysis, hypersensitivity reaction (fever, pruritus, rash, injections site reaction, bullous eruption), postoperative wound bleeding, skin necrosis, subdural hematoma, thrombosis (associated with heparin-induced thrombocytopenia). Spinal or epidural hematomas can occur following neuraxial anesthesia or spinal puncture, resulting in paralysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156465\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dalteparin (eg, pruritus, rash, anaphylactic reactions), heparin, pork products, or any component of the formulation; history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis; active major bleeding; patients with unstable angina, non-Q-wave MI, or prolonged venous thromboembolism prophylaxis undergoing epidural/neuraxial anesthesia.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Use of dalteparin in patients with current HIT or HIT with thrombosis is <b>not</b> recommended and considered contraindicated due to high cross-reactivity to heparin-platelet factor-4 antibody (Guyatt [ACCP], 2012; Warkentin 1999).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Septic endocarditis, major blood clotting disorders; acute gastroduodenal ulcer; cerebral hemorrhage; severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; other diseases that increase risk of hemorrhage; injuries to and operations on the CNS, eyes, and ears</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156449\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Bleeding may occur at any site during therapy. Monitor patient closely for signs or symptoms of bleeding. Risk factors for bleeding include patients with bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmology surgery; in patients treated concomitantly with other drugs known to cause bleeding (eg, platelet inhibitors, SSRIs); recent GI bleeding; thrombocytopenia or platelet defects; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Discontinue if bleeding occurs; use is contraindicated with active major bleeding. Protamine may be considered as a partial reversal agent in overdose situations (consult Protamine monograph for dosing recommendations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Monitor for hyperkalemia. Heparin can cause hyperkalemia by affecting aldosterone; similar reactions could occur with LMWHs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Thrombocytopenia with thrombosis, amputation, and death have been observed; HIT may occur. Use is contraindicated in patients with a history of HIT or HIT with thrombosis. Interrupt or discontinue therapy in patients with platelet counts &lt;100,000/mm<sup>3</sup> and/or thrombosis related to initiation of dalteparin especially when associated with a positive in vitro test for antiplatelet antibodies. Use caution in patients with thrombocytopenia or platelet defects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; accumulation may occur with repeated dosing increasing the risk for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; accumulation may occur with repeated dosing increasing the risk for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: There is no consensus for adjusting/correcting the weight-based dosage of LMWH for patients who are morbidly obese (BMI &ge;40 kg/m<sup>2</sup>). Monitoring of anti-Xa levels 4 hours after the dose may be warranted. The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (Gould 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and should not be used in pregnant women. In neonates, large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;); the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuraxial anesthesia:<b> [US Boxed Warning]: Epidural or spinal hematomas, including subsequent long term or permanent paralysis, may occur in patients anticoagulated with LMWH or heparinoids who are receiving neuraxial anesthesia (epidural or spinal anesthesia) or undergoing spinal puncture. Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters, a history of spinal deformity or spinal surgery, or a history of traumatic or repeated epidural or spinal punctures. Optimal timing between neuraxial procedures and dalteparin administration is not known.</b> Delay placement or removal of catheter for at least 12 hours after administration of 2,500 units once daily, at least 15 hours after the administration of 5,000 units once daily, and at least 24 hours after the administration of higher doses (200 units/kg once daily, 120 units/kg twice daily) and consider doubling these times in patients with creatinine clearance &lt;30 mL/minute; risk of neuraxial hematoma may still exist since antifactor Xa levels are still detectable at these time points. Upon removal of catheter, consider delaying next dose of dalteparin for at least 4 hours. Frequently monitor patients for signs and symptoms of neurological impairment (eg, midline back pain, sensory and motor deficits, bowel and/or bladder dysfunction) following anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture. If neurological compromise is noted, urgent treatment is necessary. If spinal hematoma is suspected, diagnose and treat immediately; spinal cord decompression may be considered although it may not prevent or reverse neurological sequelae. Use is contraindicated in patients with unstable angina and non-Q-wave MI, or for prolonged venous thromboembolism prophylaxis in patients who will be undergoing epidural/neuraxial anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299121\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156453\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9319&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithrombin: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Canagliflozin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: Heparins (Low Molecular Weight) may increase the serum concentration of Palifermin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.  Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156468\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported (Bates 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">LMWH is recommended over unfractionated heparin for the treatment of acute VTE in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors. LMWH should be discontinued at least 24 hours prior to induction of labor or a planned cesarean delivery. For women undergoing cesarean section and who have additional risk factors for developing VTE, the prophylactic use of LMWH may be considered. For women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt 2012). LMWH may also be used in women with mechanical heart valves (consult current guidelines for details) (Bates 2012, Nishimura 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Multiple-dose vials contain benzyl alcohol (avoid in pregnant women due to association with gasping syndrome in premature infants); use of preservative-free formulation is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801185\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Anti-xa activity was noted in breast milk of women receiving prophylactic doses of dalteparin. Oral absorption of low molecular weight heparin (LMWH) is expected to be low. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Available guidelines note the use of LMWH may be continued in breastfeeding women (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156457\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic CBC including platelet count; stool occult blood tests. Monitoring of PT and PTT is not necessary. Once patient has received 3 to 4 doses, anti-Xa levels, drawn 4 to 6 hours after dalteparin administration, may be used to monitor effect in patients with severe renal impairment or if abnormal coagulation parameters or bleeding should occur. For patients &gt;190 kg, if anti-Xa monitoring is available, adjusting dose based on anti-Xa levels is recommended; if anti-Xa monitoring is unavailable, reduce dose if bleeding occurs (Nutescu 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Signs and symptoms of neurological impairment (eg, midline back pain, sensory/motor deficits, bowel and/or bladder dysfunction).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4802962\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recurrent VTE prophylaxis in pregnant women: Peak anti-Xa concentrations: 0.2 to 0.6 units/mL (Bates  2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of venous thromboembolism: Peak anti-Xa concentration target (measured 4 hours after administration): <i>Once-daily dosing:</i> 1.05 anti-Xa units/mL (Garcia, 2012); per the manufacturer, target anti-Xa range is 0.5 to 1.5 units/mL (measured 4 to 6 hours after administration and after patient received 3 to 4 doses).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156448\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Low molecular weight heparin analog with a molecular weight of 4,000 to 6,000 daltons; the commercial product contains 3% to 15% heparin with a molecular weight &lt;3,000 daltons, 65% to 78% with a molecular weight of 3,000 to 8,000 daltons and 14% to 26% with a molecular weight &gt;8,000 daltons; while dalteparin has been shown to inhibit both factor Xa and factor IIa (thrombin), the antithrombotic effect of dalteparin is characterized by a higher ratio of antifactor Xa to antifactor IIa activity (ratio = 4)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156464\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Anti-Xa activity: Within 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &gt;12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 40 to 60 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Low affinity for plasma proteins (Howard 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 87% &plusmn; 6%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (route dependent):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Mean terminal half-life: 2.1 &plusmn; 0.3 hours (40 unit/kg/dose) to 2.3 &plusmn; 0.4 hours (60 unit/kg/dose); mean terminal half-life (anti-Xa activity): 5.7 &plusmn; 2.0 hours (5,000 unit dose in chronic renal impairment requiring hemodialysis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Mean terminal half-life: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: SubQ: Anti-Xa activity: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily renal (Howard 1997)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422208\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fragmin Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 units/0.2 mL (0.2 mL): $30.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 units/0.2 mL (0.2 mL): $49.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7500 unit/0.3 mL (0.3 mL): $73.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 units/mL (1 mL): $98.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12500 units/0.5 mL (0.5 mL): $123.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15000 unit/0.6 mL (0.6 mL): $147.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18000 units (0.72 mL): $177.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">95000 unit/3.8ml (3.8 mL): $846.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156469\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Conpac (TW);</li>\n      <li>Eurodal (PH);</li>\n      <li>Fragmin (AE, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, FI, GB, GR, HK, HN, HR, HU, IE, IL, IN, IQ, IR, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, LY, MT, NL, NO, NZ, OM, PE, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SY, TR, TW, YE, ZA, ZW);</li>\n      <li>Fragmin P Forte (DE);</li>\n      <li>Fragmine (FR);</li>\n      <li>Frahmin (UA);</li>\n      <li>Ligofragmin (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e691-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo; <i>J Am Coll Cardiol</i>, 2002, 40(7):1366-74. Available at: http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm. Accessed May 20, 2003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/12383588/pubmed\" target=\"_blank\" id=\"12383588\">12383588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douketis J, Cook D, Meade M, et al, &quot;Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin: An Assessment of Safety and Pharmacodynamics: the DIRECT Study,&quot; <i>Arch Intern Med</i>, 2008, 168(16):1805-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/18779469/pubmed\" target=\"_blank\" id=\"18779469\">18779469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2, suppl): e326S-e350S<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/22315266/pubmed\" target=\"_blank\" id=\"22315266\">22315266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8865530\"></a>Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al, &ldquo;Once-Daily Subcutaneous Dalteparin, a Low Molecular Weight Heparin, for the Initial Treatment of Acute Deep Vein Thrombosis,&rdquo; <i>Thromb Haemost</i>, 1996, 76(2):195-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/8865530/pubmed\" target=\"_blank\" id=\"8865530\">8865530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fragmin (dalteparin) [prescribing information]. New York, NY: Pfizer; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fragmin (dalteparin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frostfeldt G, Ahlberg G, Gustafsson G, et al, &ldquo;Low Molecular Weight Heparin (Dalteparin) as Adjunctive Treatment of Thrombolysis in Acute Myocardial Infarction - A Pilot Study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II), <i>J Am Coll Cardiol</i>, 1999, 33(3):627-33.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MK, Garcia DA, Wren SM, et al, &ldquo;Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e227-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/22315263/pubmed\" target=\"_blank\" id=\"22315263\">22315263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard PA, &ldquo;Dalteparin: A Low-Molecular-Weight-Heparin,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(2):192-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/9034422/pubmed\" target=\"_blank\" id=\"9034422\">9034422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Invasive Compared With Noninvasive Treatment in Unstable Coronary-Artery Disease: FRISC II Prospective Randomised Multicentre Study. Fragmin&reg; and Fast Revascularisation During Instability in Coronary Artery Disease Investigators,&rdquo; <i>Lancet</i>, 1999, 354(9180):708-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/10475181/pubmed\" target=\"_blank\" id=\"10475181\">10475181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo; <i>Circulation</i>, 2011, 123(16):1788-830.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/21422387/pubmed\" target=\"_blank\" id=\"21422387\">21422387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein W, Buchwald A, Hillis SE, et al, &ldquo;Comparison of Low Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease. Fragmin&reg; in Unstable Coronary Artery Disease Study,&rdquo; <i>Circulation</i>, 1997, 96(1):61-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/9236418/pubmed\" target=\"_blank\" id=\"9236418\">9236418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kontny F, Dale, J Abildgaard U, et al, &ldquo;Randomized Trial of Low Molecular Weight Heparin (Dalteparin) in Prevention of Left Ventricular Thrombus Formation and Arterial Embolism After Acute Anterior Myocardial Infarction: The Fragmin&reg; in Acute Myocardial Infarction (FRAMI) Study,&rdquo; <i>J Am Coll Cardiol</i>, 1997, 30(4):962-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/9316525/pubmed\" target=\"_blank\" id=\"9316525\">9316525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10739374\"></a>Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. <i>Thromb Haemost</i>. 2000;83(2):209-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/10739374/pubmed\" target=\"_blank\" id=\"10739374\">10739374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee AY, Levine MN, Baker RI, et al, &ldquo;Low-Molecular-Weight Heparin Versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer,&rdquo; <i>N Engl J Med</i>, 2003, 349(2):146-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/12853587/pubmed\" target=\"_blank\" id=\"12853587\">12853587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee AY, Rickels FR, Julian JA, et al, &ldquo;Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism,&rdquo; <i>J Clin Oncol</i>, 2005, 23(10):2123-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/15699480/pubmed\" target=\"_blank\" id=\"15699480\">15699480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long-Term Low-Molecular-Mass Heparin in Unstable Coronary-Artery Disease: FRISC II Prospective Randomised Multicentre Study. Fragmin&reg; and Fast Revascularization During Instability in Coronary Artery Disease Investigators,&rdquo; <i>Lancet</i>, 1999, 354(9180):701-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Low-Molecular-Weight Heparin During Instability in Coronary Artery Disease, Fragmin&reg; During Instability in Coronary Artery Disease (FRISC) Study Group,&rdquo; <i>Lancet</i>, 1996, 347(9001):561-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/8596317/pubmed\" target=\"_blank\" id=\"8596317\">8596317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Bohlke K, Khorana AA, et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. <i>J Clin Oncol</i>. 2015;33(6):654-656. doi: 10.1200/JCO.2014.59.7351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/25605844/pubmed\" target=\"_blank\" id=\"25605844\">25605844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(17):2189-2204. doi: 10.1200/JCO.2013.49.1118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/23669224/pubmed\" target=\"_blank\" id=\"23669224\">23669224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mechanick JI, Kushner RF, Sugerman HJ, et al, &ldquo;American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic &amp; Bariatric Surgery Medical Guidelines for Clinical Practice for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient,&rdquo; <i>Obesity</i>, 2009, 17(Suppl 1):1-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/19319140/pubmed\" target=\"_blank\" id=\"19319140\">19319140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagge J, Crowther M, and Hirsh J, &ldquo;Is Impaired Renal Function a Contraindication to the Use of Low-Molecular Weight Heparin?&rdquo; <i>Arch Intern Med</i>, 2002, 162(22):2605-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/12456233/pubmed\" target=\"_blank\" id=\"12456233\">12456233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu EA and Dager W, &ldquo;Heparin, Low Molecular Weight Heparin, and Fondaparinux,&rdquo; <i>Managing Anticoagulation Patients in the Hospital</i>, Gulseth M ed, American Society of Health-System Pharmacists&reg;, Bethesda, MD: 2007, 181.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu EA, Spinler SA, Wittkowsky A, et al, &ldquo;Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings,&rdquo; <i>Ann Pharmacother</i>, 2009, 43(6):1064-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/19458109/pubmed\" target=\"_blank\" id=\"19458109\">19458109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, &ldquo;Dalteparin versus Unfractionated Heparin in Critically Ill Patients,&rdquo; <i>N Engl J Med</i>, 2011, 364(14):1305-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/21417952/pubmed\" target=\"_blank\" id=\"21417952\">21417952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Savage KJ, Wells PS, Schulz V, et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. <i>Thromb Haemost</i>. 1999;82(3):1008-1010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/10494754/pubmed\" target=\"_blank\" id=\"10494754\">10494754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stobe J, Siegemund A, Achenbach H, et al, &ldquo;Evaluation of the Pharmacokinetics of Dalteparin in Patients With Renal Insufficiency,&rdquo; <i>Int J Clin Pharmacol Ther</i>, 2006, 44(10):455-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/17063975/pubmed\" target=\"_blank\" id=\"17063975\">17063975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallentin L, &ldquo;ASSENT 3 PLUS,&rdquo; [Paper presented at] American Heart Association 75th Scientific Sessions, November 17-20, 2002; Chicago, Ill.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warad D, Rao AN, Mullikin T, et al. A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience. <i>Thromb Res</i>. 2015;136(2):229-233.[<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/26026634/pubmed\" target=\"_blank\" id=\"26026634\">26026634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE and Barkin RL, &ldquo;Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia,&rdquo; <i>Pharmacotherapy</i>, 1999, 19(2):181-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/10030768/pubmed\" target=\"_blank\" id=\"10030768\">10030768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15824291\"></a>Wells PS, Anderson DR, Rodger MA, et al, &ldquo;Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism,&rdquo; <i>Arch Intern Med</i>, 2005, 165(7):733-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/15824291/pubmed\" target=\"_blank\" id=\"15824291\">15824291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11408748\"></a>Wilson SJ, Wilbur K, Burton E, et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. <i>Haemostasis.</i> 2001;31(1):42-48. doi: 10.1159/000048043.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/11408748/pubmed\" target=\"_blank\" id=\"11408748\">11408748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong GC, Giugliano RP, and Antman EM, &ldquo;Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention,&rdquo; <i>JAMA</i>, 2003, 289(3):331-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/12525234/pubmed\" target=\"_blank\" id=\"12525234\">12525234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zed PJ, Tisdale JE, and Borzak S, &ldquo;Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes,&rdquo; <i>Arch Intern Med</i>, 1999, 159(16):1849-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalteparin-drug-information/abstract-text/10493315/pubmed\" target=\"_blank\" id=\"10493315\">10493315</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9319 Version 172.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708690\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156480\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156481\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F156518\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156483\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156484\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F4804012\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7676342\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330557\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156459\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F156445\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F156462\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F156460\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25590042\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174521\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156452\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156465\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156449\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299121\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156453\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156468\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4801185\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F156457\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F4802962\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156448\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F156464\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422208\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F156469\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9319|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dalteparin-patient-drug-information\" class=\"drug drug_patient\">Dalteparin: Patient drug information</a></li><li><a href=\"topic.htm?path=dalteparin-pediatric-drug-information\" class=\"drug drug_pediatric\">Dalteparin: Pediatric drug information</a></li></ul></div></div>","javascript":null}